Galectin-1 Inhibitor OTX008 Induces Tumor Vessel

International Journal of

Molecular Sciences Communication

Galectin-1 Inhibitor OTX008 Induces Tumor Vessel Normalization and Tumor Growth Inhibition in Human Head and Neck Squamous Cell Carcinoma Models Nathan A. Koonce 1,2 , Robert J. Griffin 1, * and Ruud P. M. Dings 1, * 1 2

*

ID

Department of Radiation Oncology, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA; [email protected] National Center for Toxicological Research, Food and Drug Administration, Jefferson, AR 72079, USA Correspondence: [email protected] (R.J.G.); [email protected] (R.P.M.D.); Tel.: +1-501-526-7873 (R.J.G.); +1-501-526-7876 (R.P.M.D.); Fax: +1-501-526-5934 (R.J.G. & R.P.M.D.)

Received: 6 November 2017; Accepted: 5 December 2017; Published: 9 December 2017

Abstract: Galectin-1 is a hypoxia-regulated protein and a prognostic marker in head and neck squamous cell carcinomas (HNSCC). Here we assessed the ability of non-peptidic galectin-1 inhibitor OTX008 to improve tumor oxygenation levels via tumor vessel normalization as well as tumor growth inhibition in two human HNSCC tumor models, the human laryngeal squamous carcinoma SQ20B and the human epithelial type 2 HEp-2. Tumor-bearing mice were treated with OTX008, Anginex, or Avastin and oxygen levels were determined by fiber-optics and molecular marker pimonidazole binding. Immuno-fluorescence was used to determine vessel normalization status. Continued OTX008 treatment caused a transient reoxygenation in SQ20B tumors peaking on day 14, while a steady increase in tumor oxygenation was observed over 21 days in the HEp-2 model. A >50% decrease in immunohistochemical staining for tumor hypoxia verified the oxygenation data measured using a partial pressure of oxygen (pO2 ) probe. Additionally, OTX008 induced tumor vessel normalization as tumor pericyte coverage increased by approximately 40% without inducing any toxicity. Moreover, OTX008 inhibited tumor growth as effectively as Anginex and Avastin, except in the HEp-2 model where Avastin was found to suspend tumor growth. Galectin-1 inhibitor OTX008 transiently increased overall tumor oxygenation via vessel normalization to various degrees in both HNSCC models. These findings suggest that targeting galectin-1—e.g., by OTX008—may be an effective approach to treat cancer patients as stand-alone therapy or in combination with other standards of care. Keywords: galectin-1 inhibitor; OTX008; Avastin; Anginex; hypoxia; pimonidazole; vessel normalization

1. Introduction Agents that target the tumor microenvironment and inhibit angiogenesis have shown promise as therapeutics in solid tumors. Although anti–vascular endothelial growth factor (VEGF) agents like bevacizumab (AvastinTM , a humanized monoclonal antibody against VEGF; Genentech (South San Francisco, CA, USA)) are perhaps most discussed [1], many other compounds have been identified and are currently in various phases of clinical cancer trials [2,3]. Nevertheless, some angiogenesis inhibitors and vascular disruptors are ineffective or cause unwanted biological side effects [4], which underscores the need for more diverse compounds and/or treatment strategies. Although it is critical to recognize that anti-angiogenesis treatment can take the form of more than growth factor pathway inhibition alone, few other agents have made the clinical impact of Avastin.

Int. J. Mol. Sci. 2017, 18, 2671; doi:10.3390/ijms18122671

www.mdpi.com/journal/ijms

Int. J. Mol. Sci. 2017, 18, 2671

2 of 9

Galectins are a family of carbohydrate-binding lectins that share a conserved carbohydrate recognition domain by binding to β-galactoside-containing glycoconjugates. Galectins promote cell-cell and cell-matrix interactions during cancer development and progression. Our recent results have validated (galectin-1) gal-1 as a viable cancer target with broad potential [5,6], as differential stromal elevation of gal-1 over the tumor parenchyma has been reported in several cancers, including those of head and neck, ovary, breast, brain, colon, skin, and prostate [7–11]. To date, most known galectin antagonists are glycomimetics and are derivatives or analogs of β-galactoside, targeting the canonical carbohydrate-binding site of galectins. These include aryl O- and S-galactosides and lactosides [12,13], carbohydrate-based triazoles and isoxazoles [14], O-galactosyl aldoximes [15], phenyl thio-β-D-galactopyranoside analogs [16], thioureido N-acetyllactosamine derivatives [17], talosides [18], and various multivalent sugar-based compounds [19]. We have previously reported on the design of Anginex, a 33mer amphipathic peptide that targets gal-1 [5,20]. While antibodies and peptides can be effective, small molecules tend to be advantageous in regards to bioavailability, immunogenic activation, degradation, and ability to scale up. We employed the calix[4]arene scaffold for the development of a peptidomimetic of Anginex because it approximated the molecular dimensions and surface topology of key spatially-related amino acid residues in Anginex [21]. We identified OTX008 to have more promising biological properties than Anginex [22] and discovered that OTX008 is an allosteric inhibitor of gal-1 as it binds at a different site than the canonical carbohydrate binding site [23]. Previous studies have identified gal-1 as a negative prognosticator in oral squamous cell carcinoma (OSCC) and human head and neck squamous cell carcinoma (HNSSC) [24,25]. Here, we investigated whether OTX008 can normalize tumor vasculature resulting in improved tumor oxygenation and subsequent tumor growth inhibition as compared to Anginex and Avastin in two HNSSC models, namely SQ20B and HEp-2. Whereas SQ20B has mutated p53 and is resistant to radiation but sensitive to OTX008, HEp-2 is an HNSSC epithelial cell line derived from human epidermoid carcinoma of the larynx, which is resistant to both standard radiochemotherapy regiments as well as OTX008 [26]. 2. Results and Discussion 2.1. OTX008 Increases Overall Tumor Oxygenation Repeated daily treatment with OTX008 resulted in an increased overall tumor oxygenation (pO2 ) up to day 14 of treatment (compared with vehicle-treated mice) in the SQ20B tumor model (Figure 1A). After day 14, tumor oxygenation decreased to levels in line with those measured in vehicle-treated mice. In contrast, in the HEp-2 tumor mouse model overall tumor oxygenation levels were steadily elevated throughout OTX008 treatment as compared to vehicle (control) treated mice (Figure 1B). In both models, this improvement in tumor oxygenation was comparable with the average increases induced by either Anginex or Avastin (Figure 1). Individual tumor oxygenation values for Anginex and Avastin in time for either model can be found in Figures S1 and S2. Overall, the results in the SQ20B and the HEp-2 models reiterated the theory that transient or sustained vessel normalization is not solely a VEGF-dependent phenomenon and moreover is seen in multiple solid tumor models including HNSSC. However, it is also interesting to note that the “tumor oxygenation window” did not occur in all tumor models, as the HEp-2 model displayed improved oxygenation throughout the study. Previously, other tumor mouse models and human clinical data have shown that this window occurs earlier, around day 3 through 5 after commencement of treatment [11,27]. The tumors in these previous studies were in general larger at the beginning of the treatment, which may have accounted for the more rapid change in oxygenation levels. The measurement of tumor oxygenation with various semi-invasive approaches may also influence the results obtained. Specifically, in the current study we sampled partial oxygenation pressure with an inserted fiber optic probe over several weeks at 1 to 3 points in each tumor were viable baseline oxygenation levels were found, thus intentionally avoiding necrotic or anoxic regions. Other invasive probes collect 50–100 point measurements and thus may

Int. Mol. Sci. Sci. 2017, 18, 18, 2671 2671 Int. J.J. Mol. Int. J. Mol. Sci. 2017, 18, 2017, 2671

3 of 9

Int. J. Mol. Sci. 2017, 18, 2671

of 99 33 of 3 of 9

oxygenation levels found, were found, found, thus intentionally intentionally avoiding necrotic or anoxic anoxic regions. Other oxygenation were thus avoiding or oxygenation levels levels were thus intentionally avoiding necroticnecrotic or anoxic regions.regions. Other Other invasive probes collect 50–100 point measurements and thus may be more influenced by the amount invasive collect 50–100 point measurements and thus more influenced by the amount invasive probes probes collect 50–100 point measurements and thus may bemay morebeinfluenced by the amount of necrotic volume being sampled [11,27]. It is also likely that this window varies due tothat origin, be more influenced by the amount of necrotic volume being sampled [11,27]. It is also likely this of necrotic volume being sampled [11,27]. It is also likely that this window varies to origin, of necrotic volume being sampled [11,27]. It is also likely that this window varies due to due origin, location, or growth rate of the particular cancer. window varies due to origin, location, or growth rate of the particular cancer. location, or growth rate of the particular cancer. location, or growth rate of the particular cancer.

Figure 1. The Theofeffect effect of OTX008 OTX008 ontumor globalpO tumor pOtime. over time. time. tumor GlobalpO tumor pO22 is is transiently transiently Figure 1. of OTX008 on global tumor pO 22 over time. Global tumor pO Figure 1. The effect OTX008 on global 2 over 2 is transiently Figure 1. The effect of on global tumor pO Global tumor pO 2 overGlobal 2 is transiently increased by OTX008 in SQ20B (A) and HEP2 (B) tumors as measured by fiber-optic oxygen sensor. increased by OTX008 in SQ20B (A) and HEP2 (B) tumors as measured by fiber-optic oxygen increased by OTX008 in SQ20B and (A) HEP2 tumors measured by fiber-optic oxygen sensor. increased by OTX008 in(A) SQ20B and(B) HEP2 (B) as tumors as measured by fiber-optic oxygensensor. sensor. Treatments: Control (C; --), OTX008 (--), Anginex (Ax; --), and Avastin (Av; --). Points, Treatments: Control (C; --), OTX008 (--), Anginex (Ax; --), and Avastin (Av; --). Points, Treatments: ControlControl (C; --), (--),(-Anginex (Ax;(Ax; --), and Points,average Treatments: (C; OTX008 --), OTX008 -), Anginex -#-), andAvastin Avastin(Av; (Av; --). - -). Points, average mean (±pO SEM) pO 2 value value derived from the stabilized reading over 60 sslocation period at one one (± SEM) pO 2derived derived from the stabilized over aa one 60 period at mean SEM) derived from the the stabilized reading overreading aover 60 s aperiod to averageaverage mean(±(±mean SEM)pO 2 value from stabilized reading 60 s at period at one (four 2 value location (four to seven mice per day per experimental group). The dotted line represents the average location (four to seven mice per day per experimental group). The dotted line represents the average seven mice per day per experimental group). The dotted line represents the average pO mean of location (four to seven mice per day per experimental group). The dotted line represents the average 2 mean of the the control. control. pOof 22control. mean of pO the the control. pO2 mean

2.2. OTX008 OTX008 Inhibits Tumor Growth Growth without Apparent Toxicity 2.2. Tumor Growth without Apparent Toxicity 2.2. OTX008 InhibitsInhibits Tumor Growth withoutwithout Apparent ToxicityToxicity 2.2. OTX008 Inhibits Tumor Apparent In aaa subsequent subsequent set of of experiments, experiments, mice inoculated inoculated with SQ20B SQ20B or HEp-2 HEp-2 tumor cells were were In subsequent set experiments, mice with or cells In a subsequent set of experiments, mice inoculated with SQ20B or HEp-2 tumor tumor cells were In set of mice inoculated with SQ20B or HEp-2 tumor cells were randomized andtreated treated withOTX008 OTX008 (qd, 10mg/kg, mg/kg, i.p.Anginex 7),Anginex Anginex (qd, 10mg/kg, mg/kg, i.p.or 7) or or randomized and treated with OTX008 (qd, 10 mg/kg, i.p. 7), Anginex (qd, 10 mg/kg, i.p. n randomized and treated with OTX008 (qd, 10(qd, mg/kg, i.p. n =i.p. 7), (qd, 10(qd, mg/kg, i.p. n = i.p. 7) randomized and with 10 nnn=== 7), 10 nn === 7) 7) or 3 Avastin (once every 14 days, 10 mg/kg, i.v. n = 7) starting when tumors reached the size of ~100 mm 3 Avastin (once every 14 days, 10 mg/kg, i.v. n = 7) starting when tumors reached the size of ~100 mm AvastinAvastin (once every days, mg/kg, i.v. n = i.v. 7) starting when tumors reachedreached the sizethe of size ~100ofmm . mm33... (once14 every 1410 days, 10 mg/kg, n = 7) starting when tumors ~ 100 In the the SQ20B SQ20B model OTX008 OTX008 reduced tumor growth growth on average average 25%, up to to 35% on certain certain days In reduced on 25%, up on In the SQ20B model model OTX008 reduced tumor tumor growth on average 25%, up to 35% on35% certain days days In the SQ20B model OTX008 reduced tumor growth on average 25%, up to 35% on certain days (Figure 2). This inhibition inhibition was comparable comparable to the the effects effects of Avastin Avastin in this this and model and slightly slightly better This was to of in model and (Figure(Figure 2). This2). inhibition was comparable to the effects of Avastin in this model slightly better better (Figure 2). This inhibition was comparable to the effects of Avastin in this model and slightly better than Anginex (Figure 2). In the HEp-2 tumor model this was less pronounced, whereas Avastin than Anginex (Figure 2). In the HEp-2 tumor model this was less pronounced, whereas Avastin than Anginex (Figure(Figure 2). In the tumor model was less pronounced, whereas AvastinAvastin than Anginex 2). HEp-2 In the HEp-2 tumor this model this was less pronounced, whereas caused tumor growth stabilization (Figure 3). As shown by Astorgues-Xerri et al., HEp-2 is tumor growth stabilization (Figure 3). As shown by Astorgues-Xerri et HEp-2 is causedcaused tumor growth stabilization (Figure 3). As shown by Astorgues-Xerri et al., HEp-2 is caused tumor growth stabilization (Figure 3). As shown by Astorgues-Xerri et al., HEp-2al., is inherently inherently resistant to radiochemotherapy radiochemotherapy including OTX008 [26], which couldthe explain the relatively relatively inherently to including OTX008 [26], which could explain the inherently resistant to radiochemotherapy including OTX008 [26], which could explain therelatively relatively resistant toresistant radiochemotherapy including OTX008 [26], which could explain limited limited HEp-2 tumor growth inhibition by OTX008. Additionally, in the current study OTX008 and limited HEp-2 tumor growth inhibition by OTX008. Additionally, in the current study OTX008 and limitedHEp-2 HEp-2tumor tumorgrowth growthinhibition inhibitionby byOTX008. OTX008.Additionally, Additionally,ininthe thecurrent current study OTX008 and study OTX008 and Anginex Anginex was administered administered i.p.compared daily. Astocompared compared to previous previous reports, thesuggests data suggests that Anginex was i.p. daily. As to reports, the data suggests Anginex was administered daily. As compared to previous reports, thesuggests data that that was administered i.p. i.p. daily. As previous reports, the data that administering administering OTX008 or Anginex bis in die (BID) i.p. or subcutaneous (s.q.) continuously by administering OTX008 or Anginex bis in die (BID) i.p. or subcutaneous (s.q.) continuously by administering or Anginex in i.p. dieor(BID) i.p. or subcutaneous (s.q.) continuously by OTX008OTX008 or Anginex bis in die bis (BID) subcutaneous (s.q.) continuously by osmotic mini-pump osmotic mini-pump will result in greater tumor growth inhibition [20,22,28,29]. mini-pump will result in greater tumor growth inhibition [20,22,28,29]. osmoticosmotic mini-pump will result in greater tumor growth inhibition [20,22,28,29]. will result in greater tumor growth inhibition [20,22,28,29].

Figure 2. OTX008 OTX008 inhibits SQ20B tumor growth in mice. (A) SQ20B tumor growth during the first 11 Figure 2. SQ20B tumor (A) SQ20B tumor growth during first 11 Figure 2. OTX008 inhibitstumor SQ20B tumorgrowth growth inmice. mice. (A) SQ20B tumor growth during first Figure 2. OTX008 inhibits inhibits SQ20B growth in mice.in (A) SQ20B tumor growth during the firstthe 11the days and treatment with Control (vehicle), Anginex, OTX008 and Avastin; (B) SQ20B tumor growth days and treatment with Control (vehicle), Anginex, OTX008 and Avastin; (B) SQ20B tumor growth 11treatment days and treatment with(vehicle), Control (vehicle), OTX008 and Avastin; (B)tumor SQ20Bgrowth tumor growth days and with Control Anginex, Anginex, OTX008 and Avastin; (B) SQ20B during thetreatment whole treatment treatment span with Control Control (vehicle), Anginex, OTX008 and Avastin. Treatments: during the whole span with (vehicle), Anginex, and Treatments: during the whole treatment span with Control (vehicle), Anginex, OTX008 andAvastin. Avastin. Treatments: during the whole span with Control (vehicle), Anginex, OTX008OTX008 and Avastin. Treatments: Control (vehicle; Anginex (i.p. 10 10q1d×21; mg/kg, q1d×21; q1d×21; 7; 7; --), OTX008 (i.p. 1010 mg/kg, q1d×21; --), (i.p. mg/kg, nn =n=OTX008 7; --), OTX008 (i.p. 10 mg/kg, q1d×21; == -), Anginex 10 mg/kg, 21; = -N-), OTX008 (i.p. mg/kg, 21; (vehicle; ---), ControlControl (vehicle;(vehicle; --), Anginex (i.p. 10 mg/kg, nq1d = 7;×--), (i.p. 10 mg/kg, q1d×21; n =q1d×nn 7; --), and Avastin (i.v. 10 mg/kg, q14d×2; n = 7; --). Data points represent means ± SEM (n = 7 each 7; --), and Avastin (i.v. 10 mg/kg, q14d×2; n = 7; --). Data points represent means ± SEM (n = 7 each n = 7; --), and (i.v. q14d×2; 10 mg/kg, ×2;Data n = 7; -H-). represent Data points represent means SEM (n = 7 7; --), and Avastin (i.v.Avastin 10 mg/kg, n = q14d 7; --). points means ± SEM (n = 7± each group). each group). group). group).

Int. J.J.Mol. Mol.Sci. Sci.2017, 2017,18, 18,2671 2671 Int. Int. J. Mol. Sci. 2017, 18, 2671

of 99 44 of 4 of 9

Figure 3. OTX008 inhibits HEp-2 tumor growth in mice. (A) HEp-2 tumor growth during the first 11 Figure 3. HEp-2 ininmice. (A)(A) HEp-2 tumor growth during thethe firstfirst 11 Figure 3. OTX008 OTX008inhibits inhibits HEp-2tumor tumorgrowth growth mice. HEp-2 tumor growth days and treatment with Control (vehicle), Anginex, OTX008 and Avastin; (B) HEp-2during tumor growth days andand treatment with Control (vehicle), Anginex, OTX008 and (B) growth 11 days treatment with Control (vehicle), OTX008 andAvastin; Avastin;and (B)HEp-2 HEp-2tumor tumor growth during the whole treatment span with ControlAnginex, (vehicle), Anginex, OTX008 Avastin. Treatments: during the whole treatment span with Control (vehicle), Anginex, OTX008 and Avastin. Treatments: during the whole treatment span with Control (vehicle), Anginex, OTX008 and Avastin. Treatments: Control (vehicle; --), Anginex (i.p. 10 mg/kg, q1d×21; n = 7; --), OTX008 (i.p. 10 mg/kg, q1d×21; n = Control (vehicle; --), Anginex (i.p. 10 q1d×21; n =n 7; --), OTX008 (i.p. 10 10 mg/kg, q1d×21;×n21; = Control (vehicle; - -), Anginex (i.p.q14d×2; 10mg/kg, mg/kg, ×21; =points 7; -N-), OTX008 (i.p. 7; --), and Avastin (i.v. 10 mg/kg, n = 7;q1d --). Data represent means ±mg/kg, SEM (n q1d = 7 each 7; --), and Avastin (i.v. 10 mg/kg, q14d×2; n = 7; --). Data points represent means ± SEM (n = 7 each n = 7; --), and Avastin (i.v. 10 mg/kg, q14d×2; n = 7; -H-). Data points represent means ± SEM (n = 7 group). group). each group).

In both tumor models studied, prolonged treatment with OTX008, Anginex, or Avastin In both tumor models studied, prolonged treatment with OTX008, Anginex, or Avastin In both models studied, prolonged treatment with OTX008, or Avastin revealed no tumor signs of toxicity as assessed by unaltered behavior and Anginex, normal weight gainrevealed during revealed no signs of toxicity as assessed by unaltered behavior and normal weight gain during no signs of toxicity by unaltered behavior and normalmorphologies weight gain during experiments experiments (Figureas4).assessed Upon autopsy, macroand microscopic of internal organs experiments (Figure 4). Upon autopsy, macro- and microscopic morphologies of internal organs (Figure 4).observed Upon autopsy, macro- within and microscopic morphologies were also to be normal all experimental groupsof ofinternal animals.organs were also observed were also observed to be normal within all experimental groups of animals. to be normal within all experimental groups of animals.

Figure 4. OTX008 does not show any sign of apparent toxicity. (A) In the SQ20B OTX008, Anginex Figure 4. OTX008 does not show any sign of apparent toxicity. (A) In SQ20B OTX008, Anginex toxicity. In the the OTX008, Anginex and Avastin do not show any signs of apparent toxicity as measured by SQ20B body weight fluctuation and Avastin do not not show any signs of apparent apparent toxicity as measured measured by body weight fluctuation and Avastin do signs of toxicity as body weight fluctuation during treatment; (B)show In theany HEp-2 OTX008, Anginex and Avastin do notby show any signs of apparent during (B) In In the HEp-2 OTX008, Anginex and do not not show any any signs signs of apparent apparent during treatment; treatment; (B) HEp-2 OTX008, Anginex and Avastin Avastin do show of toxicity as measured bythe body weight fluctuation during treatment. Treatments: Control (vehicle; toxicity as measured by body weight fluctuation during treatment. Treatments: Control (vehicle; toxicity as measured body weight fluctuation during treatment. Control -and -), --), Anginex (i.p. 10by mg/kg, q1d×21; n = 7; --), OTX008 (i.p. 10 Treatments: mg/kg, q1d×21; n =(vehicle; 7; --), --), Anginex (i.p. 10 mg/kg, q1d×21; n = 7; --), OTX008 (i.p. 10 mg/kg, q1d×21; n = 7; --), and Avastin (i.v. points means SEM 7 -), each Anginex (i.p.10 10mg/kg, mg/kg,q14d×2; q1d×21;nn==7;7;--). -N-),Data OTX008 (i.p.represent 10 mg/kg, q1d×±21; n =(n7;=- andgroup). Avastin Avastin (i.v. 10 mg/kg, q14d×2; n = 7; --). Data points represent means ± SEM (n = 7 each group). (i.v. 10 mg/kg, q14d×2; n = 7; -H-). Data points represent means ± SEM (n = 7 each group).

2.3. OTX008 Reduces Tumor Hypoxia and Improves Pericyte Coverage 2.3. OTX008 Reduces Tumor Hypoxia and Improves Pericyte Coverage 2.3. OTX008 Tumor Hypoxia in andaImproves Pericyte Coverage OTX008 Reduces treatment resulted decrease of SQ20B tumor hypoxia, as measured by OTX008 treatment resulted in a decrease of SQ20B tumor hypoxia, as measured by pimonidazole. Pimonidazole, a substituted 2-nitroimidazole, is preferentially in hypoxic OTX008 treatment resulted in a decrease of SQ20B istumor hypoxia,reduced as measured by pimonidazole. Pimonidazole, a substituted 2-nitroimidazole, preferentially reduced in hypoxic viable cells and Pimonidazole, forms irreversible protein adducts, which haveisbeen optimizedreduced for detection with pimonidazole. a substituted 2-nitroimidazole, preferentially in hypoxic viable cells and forms irreversible protein adducts, which have been optimized for detection with immunohistochemistry. On average,protein OTX008 reducedwhich hypoxia bybeen ~70% in SQ20B tumors (Figure 5). viable cells and forms irreversible adducts, have detection with immunohistochemistry. On average, OTX008 reduced hypoxia by ~70%optimized in SQ20B for tumors (Figure 5). These immunofluorescence results are in line with the improved oxygenation levels as determined immunohistochemistry. On results average, OTX008 byoxygenation ~70% in SQ20B tumors (Figure 5). These immunofluorescence are in line reduced with thehypoxia improved levels as determined by direct measurement of the partial of oxygen (Figureoxygenation 1). Besides the improvement of These immunofluorescence results arepressure in line with the improved as determined by direct measurement of the partial pressure of oxygen (Figure 1). Besides levels the improvement of tumor oxygenation, vessel normalization was correlated with an improvement of pericyte coverage. by direct measurement of normalization the partial pressure of oxygen (Figure 1). Besides of thepericyte improvement of tumor oxygenation, vessel was correlated with an improvement coverage. As shown and quantified innormalization Figure 5, OTX008 increased with the amount of pericyte-covered vessels by tumor oxygenation, vessel was correlated an improvement of pericyte coverage. As shown and quantified in Figure 5, OTX008 increased the amount of pericyte-covered vessels by ~40% in SQ20B tumors. in Figure 5, OTX008 increased the amount of pericyte-covered vessels by As shown and quantified ~40% in SQ20B tumors. ~40% in SQ20B tumors.

Int. J. Mol. Sci. 2017, 18, 2671 Int. J. Mol. Sci. 2017, 18, 2671

5 of 9 5 of 9

Figure 5. 5. Hypoxia content in in SQ20B tumor tissue afterafter OTX008 treatment. (A) Figure Hypoxiaand andpericyte pericyte content SQ20B tumor tissue OTX008 treatment. Immunofluorescence analysis of of SQ20B tumors treated (A) Immunofluorescence analysis SQ20B tumorscross-sections cross-sectionsfrom fromOTX008 OTX008 or or vehicle vehicle treated animals at 14 days after the beginning of OTX008 therapy. Microvessel density is revealed by CD31 animals at 14 days after the beginning of OTX008 therapy. Microvessel density is revealed by CD31 antibody staining (white), pericytes by alpha-smooth muscle actin (αSMA; green) and hypoxia by antibody staining (white), pericytes by alpha-smooth muscle actin (αSMA; green) and hypoxia by pimonidazole (red). Magnifications as indicated; (B) Quantification of hypoxia by pimonidazole pimonidazole (red). Magnifications as indicated; (B) Quantification of hypoxia by pimonidazole positive regions; of of pericytes by α positive cells. cells. Data isData depicted as meansas± positive regions; (C) (C)Quantification Quantification pericytes by-SMA α -SMA positive is depicted SEM and normalized to the controls, set at 100%; * p < 0.05 (Student’s t-test). means ± SEM and normalized to the controls, set at 100%; * p < 0.05 (Student’s t-test).

Overall, our results show that OTX008 can transiently increase overall tumor oxygenation via Overall, our results show that OTX008 can transiently increase overall tumor oxygenation via vessel normalization with varying kinetics and magnitude/duration of effects as tumors progress. vessel normalization with varying kinetics and magnitude/duration of effects as tumors progress. Since Avastin, in combination with chemotherapy is already an Food and Drug Administration Since Avastin, in combination with chemotherapy is already an Food and Drug Administration approved protocol for treatment of several tumor types [30], a gal-1 therapeutic such as Anginex or approved protocol for treatment of several tumor types [30], a gal-1 therapeutic such as Anginex or OTX008 could possibly avoid the noted systemic effects that Avastin usage promotes [2–4]. OTX008 could possibly avoid the noted systemic effects that Avastin usage promotes [2–4]. Moreover, Moreover, gal-1 inhibitors may achieve a more permissive tumor microenvironment status for gal-1 inhibitors may achieve a more permissive tumor microenvironment status for improved radiation improved radiation or chemotherapeutic treatment. or chemotherapeutic treatment. Additionally, non-peptidic topomimetic OTX008 might be advantageous over a biologic such as Additionally, non-peptidic topomimetic OTX008 might be advantageous over a biologic such Avastin based on the drug properties. Whereas biologics, antibodies included, are relatively large as Avastin based on the drug properties. Whereas biologics, antibodies included, are relatively large proteins (up to 150 kDa) they differ from small molecules in their cost, production, administration, proteins (up to 150 kDa) they differ from small molecules in their cost, production, administration, and clinical efficacy. Larger proteins and antibodies are predominantly more difficult to produce and clinical efficacy. Larger proteins and antibodies are predominantly more difficult to produce and characterize as protein folding and tertiary structure are essential for their efficacy, resulting in and characterize as protein folding and tertiary structure are essential for their efficacy, resulting in increased costs. Due to these inherent challenges, specificity, scale up, purity, and batch consistency increased costs. Due to these inherent challenges, specificity, scale up, purity, and batch consistency can also be more demanding [31]. Moreover biologics, Avastin included, are generally administered can also be more demanding [31]. Moreover biologics, Avastin included, are generally administered intravenously as they are likely to be digested when taken orally [32]. Small molecules or synthetics intravenously as they are likely to be digested when taken orally [32]. Small molecules or synthetics chemicals on the other hand are often orally available and absorbed into the bloodstream via the chemicals on the other hand are often orally available and absorbed into the bloodstream via the intestinal wall due to their small size and chemical composition. Additionally, larger proteins are intestinal wall due to their small size and chemical composition. Additionally, larger proteins are assumed more likely to be immunogenic and less efficient in tissue penetration, tumor retention, and assumed more likely to be immunogenic and less efficient in tissue penetration, tumor retention, and blood clearance than small molecules [32]. blood clearance than small molecules [32]. Subsequently, it would be pertinent to elucidate whether the increase in oxygenation caused by Subsequently, it would be pertinent to elucidate whether the increase in oxygenation caused OTX008 enhances the effect of radiation therapy in vivo, especially if radiation at a large dose per by OTX008 enhances the effect of radiation therapy in vivo, especially if radiation at a large dose fraction could be applied at the peak of tumor oxygenation observed. Furthermore, there may be per fraction could be applied at the peak of tumor oxygenation observed. Furthermore, there may opportunities to enhance the effects of various chemotherapeutic agents due to the improved be opportunities to enhance the effects of various chemotherapeutic agents due to the improved physiological state of tumors during OTX008 treatment. By administering chemotherapy during the physiological state of tumors during OTX008 treatment. By administering chemotherapy during the OTX008 oxygenation window, we would expect to maximize drug penetration/diffusion and overall OTX008 oxygenation window, we would expect to maximize drug penetration/diffusion and overall coverage of the tumor. Recent preclinical and clinical reports on gal-1 playing a principal role in coverage of the tumor. Recent preclinical and clinical reports on gal-1 playing a principal role in tumor tumor progression, therapeutic resistance, and metastatic potential of multiple tumor types [33–35] highlight the translational potential of OTX008 and other gal-1 inhibitors in development.

Int. J. Mol. Sci. 2017, 18, 2671

6 of 9

progression, therapeutic resistance, and metastatic potential of multiple tumor types [33–35] highlight the translational potential of OTX008 and other gal-1 inhibitors in development. 3. Materials and Methods 3.1. Test Article and Control Reagents OTX008 (also known as PTX008 or 0118) was reconstituted in H2 O at a stock concentration of 1 mg/ml and stored at −80 ◦ C [22]. Anginex was manufactured and obtained from BioMedical Genomics Center at the University of Minnesota (Minneapolis, MN, USA) and formulated identical to OTX008 and stored at 2–8 ◦ C, as before [36]. OTX008 and Anginex were given daily for 21 days (q1d×21) in alternating intraperitoneal (i.p.) locations at 10 mg/kg. Avastin™ (bevacizumab, a humanized monoclonal antibody against VEGF) was obtained from the University of Arkansas for Medical Sciences (UAMS) pharmacy, manufactured by Genentech). The antibody is provided at a stock concentration of 25 mg/mL and stored at 2–8 ◦ C. Avastin was given once every 14 days (q14d×2) intravenously (i.v.) at 10 mg/kg. 3.2. Tumor Models Experiments were approved by the University of Arkansas for Medical Sciences Institutional Animal Care and Use Committee (Animal Usage Protocol #3157; 05 17 2013) and performed in accordance with relevant regulations and guidelines. For the xenograft models, female athymic nude mice (Nu/Nu, 5–6 weeks old) were inoculated into the right flank s.c. with tumor cells and when tumors reached a size of ~100 mm3 , animals were randomly assigned to treatment groups and administration of study drug was commenced. In total, 92 animals were inoculated and a total of 76 tumor-bearing animals were selected for randomization before the initiation of the intervention. SQ20B—radio-resistant HNSCC SQ20B carries a p53 mutation and has a constitutively active mutation in epidermal growth factor receptor (EGFR) resulting in robust Akt (protein kinase B) signaling [26,37–39]. It was shown previously that this cell line is sensitive to OTX008 in different in vitro and in vivo experiments [40]. HEp-2—an epithelial cell line derived from human epidermoid carcinoma of the larynx. This cell line is more resistant to current standard chemotherapeutic agents and it is more resistant in vitro to OTX008 as compared to HNSCC SQ20B [40]. 3.3. Tumor Growth Subcutaneous tumors were measured with a caliper prior to starting treatment (prior to randomization into treatment groups) and then once a day during treatment. Tumor volumes were calculated based on the equation (a2 × b)/2 where a is the shortest and b is the longest diameter of the tumor (width or length) [39]. 3.4. Tumor Oxygenation Studies Tumor partial pressure of oxygen (pO2 ) was measured using a fiber-optic oxygen sensor (Oxylite™, Oxford Optronix, Oxford, UK) [41]. The probe was inserted via a needle track to approximately the center of the three dimensional tumor mass and readings were recorded for 3 min. Final values were based on the stabilized value over a 60 s period at one location. Once tumors grew to a larger size, the probe was moved to one or two more locations and readings recorded over 3 min at each position. The readings were based on four to seven mice per day per experimental group. 3.5. Tumor Vessel Density and Pericyte Staining Extracted tumors were either fixed in 10% formalin or embedded in tissue freezing medium and snap frozen in liquid nitrogen. Formalin-fixed tumors embedded in paraffin or frozen tumors were cut into 5 µm sections. After rehydration and antigen retrieval, the slides were stained for

Int. J. Mol. Sci. 2017, 18, 2671

7 of 9

either vessel density (CD31 from BD Pharmingen (San Jose, CA, USA); 2nd Ab αRat-647) or pericytes (anti-alpha-smooth muscle actin, αSMA-FITC from Sigma-Aldrich (St. Louis, MO, USA)) [22]. 3.6. Tumor Hypoxia An i.p. injection of 60 mg/kg pimonidazole was given to each mouse prior to euthanasia. Pimonidazole, a substituted 2-nitroimidazole, is preferentially reduced in hypoxic viable cells and forms irreversible protein adducts, which have been optimized for detection with immunohistochemistry [42]. At 1 h post-injection, the mice were euthanized, then the tumor dissected and immediately either fixed in 10% formalin or snap frozen. Following sectioning of tumor tissue, a FITC-conjugated monoclonal antibody against protein adducts of pimonidazole was added (hypoxyprobe-1 MAb; Chemicon International, Burlington, MA, USA); 2nd Ab αRabbit-594). Images of the section were acquired and subsequently digitally and differentially quantified by morphometric analysis [11]. 3.7. Body Weight As an indirect measure of general toxicity, body weights were measured prior to starting treatment and once daily during treatment. At the end of the study by autopsy, macro- and microscopic morphologies of internal organs were inspected and recorded in all experimental groups of animals [22]. Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/12/2671/s1. Acknowledgments: This work was supported by a grant from the Arkansas Biosciences Institute and the Winthrop P. Rockefeller Cancer Institute (RPMD). The study was also supported in part by the Center for Microbial Pathogenesis and Host Inflammatory Responses grant P20GM103625 through the NIH National Institute of General Medical Sciences Centers of Biomedical Research Excellence (RPMD). The study was also supported in part by OncoEthix (Lausanne, Vaud, Switzerland). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH or the Winthrop P. Rockefeller Cancer Institute. Author Contributions: Nathan A. Koonce, Robert J. Griffin and Ruud P. M. Dings designed the work, analyzed and interpreted the data, drafted the article and critically revised the article; Nathan A. Koonce collected the data. Conflicts of Interest: The authors declare no conflicts of interest.

References 1. 2. 3. 4.

5.

6.

7. 8. 9.

Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4–25. Horsman, M.R.; Siemann, D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Res. 2006, 66, 11520–11539. [CrossRef] Potente, M.; Gerhardt, H.; Carmeliet, P. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146, 873–887. [PubMed] Lordick, F.; Geinitz, H.; Theisen, J.; Sendler, A.; Sarbia, M. Increased risk of ischemic bowel complications during treatment with bevacizumab after pelvic irradiation: Report of three cases. Int. J. Radiat. Oncol. Biol. Phys. 2006, 64, 1295–1298. [CrossRef] Thijssen, V.L.; Postel, R.; Brandwijk, R.J.; Dings, R.P.; Nesmelova, I.; Satijn, S.; Verhofstad, N.; Nakabeppu, Y.; Baum, L.G.; Bakkers, J.; et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc. Natl. Acad. Sci. USA 2006, 103, 15975–15980. [CrossRef] [PubMed] Thijssen, V.L.; Barkan, B.; Shoji, H.; Aries, I.M.; Mathieu, V.; Deltour, L.; Hackeng, T.M.; Kiss, R.; Kloog, Y.; Poirier, F.; et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res. 2010, 70, 6216–6224. [PubMed] Van den Brule, F.; Califice, S.; Castronovo, V. Expression of galectins in cancer: A critical review. Glycoconj. J. 2004, 19, 537–542. Camby, I.; Le Mercier, M.; Lefranc, F.; Kiss, R. Galectin-1: A small protein with major functions. Glycobiology 2006, 16, 137R–157R. [PubMed] Liu, F.T.; Rabinovich, G.A. Galectins as modulators of tumour progression. Nat. Rev. Cancer 2005, 5, 29–41. [CrossRef] [PubMed]

Int. J. Mol. Sci. 2017, 18, 2671

10. 11.

12. 13.

14.

15. 16.

17. 18. 19.

20. 21.

22.

23.

24.

25. 26.

27.

28.

8 of 9

Lefranc, F.; Mathieu, V.; Kiss, R. Galectin-1-mediated biochemical controls of melanoma and glioma aggressive behavior. World J. Biol. Chem. 2011, 2, 193–201. [PubMed] Dings, R.P.; Loren, M.; Heun, H.; McNiel, E.; Griffioen, A.W.; Mayo, K.H.; Griffin, R.J. Scheduling of radiation with angiogenesis inhibitors anginex and avastin improves therapeutic outcome via vessel normalization. Clin. Cancer Res. 2007, 13, 3395–3402. [CrossRef] [PubMed] Sirois, S.; Giguere, D.; Roy, R. A first QSAR model for galectin-3 glycomimetic inhibitors based on 3D docked structures. Med. Chem. 2006, 2, 481–489. [CrossRef] [PubMed] St-Pierre, C.; Ouellet, M.; Giguere, D.; Ohtake, R.; Roy, R.; Sato, S.; Tremblay, M.J. Galectin-1-specific inhibitors as a new class of compounds to treat hiv-1 infection. Antimicrob. Agents Chemother. 2012, 56, 154–162. [CrossRef] [PubMed] Salameh, B.A.; Leffler, H.; Nilsson, U.J. 3-(1,2,3-triazol-1-yl)-1-thio-galactosides as small, efficient, and hydrolytically stable inhibitors of galectin-3. Bioorg. Med. Chem. Lett. 2005, 15, 3344–3346. [CrossRef] [PubMed] Tejler, J.; Leffler, H.; Nilsson, U.J. Synthesis of O-galactosyl aldoximes as potent LacNAc-mimetic galectin-3 inhibitors. Bioorg. Med. Chem. Lett. 2005, 15, 2343–2345. [CrossRef] [PubMed] Cumpstey, I.; Sundin, A.; Leffler, H.; Nilsson, U.J. C2-symmetrical thiodigalactoside bis-benzamido derivatives as high-affinity inhibitors of galectin-3: Efficient lectin inhibition through double arginine-arene interactions. Angew. Chem. Int. Ed. Engl. 2005, 44, 5110–5112. [CrossRef] [PubMed] Salameh, B.A.; Sundin, A.; Leffler, H.; Nilsson, U.J. Thioureido N-acetyllactosamine derivatives as potent galectin-7 and 9N inhibitors. Bioorg. Med. Chem. 2006, 14, 1215–1220. [CrossRef] [PubMed] Collins, P.M.; Oberg, C.T.; Leffler, H.; Nilsson, U.J.; Blanchard, H. Taloside inhibitors of galectin-1 and galectin-3. Chem. Biol. Drug Des. 2012, 79, 339–346. [PubMed] Rabinovich, G.A.; Cumashi, A.; Bianco, G.A.; Ciavardelli, D.; Iurisci, I.; D’Egidio, M.; Piccolo, E.; Tinari, N.; Nifantiev, N.; Iacobelli, S. Synthetic lactulose amines: Novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006, 16, 210–220. [CrossRef] [PubMed] Dings, R.P.; van der Schaft, D.W.; Hargittai, B.; Haseman, J.; Griffioen, A.W.; Mayo, K.H. Anti-tumor activity of the novel angiogenesis inhibitor anginex. Cancer Lett. 2003, 194, 55–66. [CrossRef] Dings, R.P.; Arroyo, M.M.; Lockwood, N.A.; Van Eijk, L.I.; Haseman, J.R.; Griffioen, A.W.; Mayo, K.H. Beta-sheet is the bioactive conformation of the anti-angiogenic anginex peptide. Biochem. J. 2003, 23, 281–288. [CrossRef] [PubMed] Dings, R.P.; Chen, X.; Hellebrekers, D.M.; van Eijk, L.I.; Zhang, Y.; Hoye, T.R.; Griffioen, A.W.; Mayo, K.H. Design of nonpeptidic topomimetics of antiangiogenic proteins with antitumor activities. J. Natl. Cancer Inst. 2006, 98, 932–936. [CrossRef] [PubMed] Dings, R.P.; Miller, M.C.; Nesmelova, I.; Astorgues-Xerri, L.; Kumar, N.; Serova, M.; Chen, X.; Raymond, E.; Hoye, T.R.; Mayo, K.H. Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding. J. Med. Chem. 2012, 55, 5121–5129. [PubMed] Valach, J.; Fik, Z.; Strnad, H.; Chovanec, M.; Plzak, J.; Cada, Z.; Szabo, P.; Sachova, J.; Hroudova, M.; Urbanova, M.; et al. Smooth muscle actin-expressing stromal fibroblasts in head and neck squamous cell carcinoma: Increased expression of galectin-1 and induction of poor prognosis factors. Int. J. Cancer 2012, 131, 2499–2508. [PubMed] Noda, Y.; Kondo, Y.; Sakai, M.; Sato, S.; Kishino, M. Galectin-1 is a useful marker for detecting neoplastic squamous cells in oral cytology smears. Hum. Pathol. 2016, 52, 101–109. [CrossRef] [PubMed] Astorgues-Xerri, L.; Serova, M.; Bieche, I.; Vivier, S.; Cvitkovic, E.; Noel, K.; Raymond, E.; Faivre, S. Effects of PTX-008, a non-peptidic topomimetic targeting galectin-1 in human epithelial cancer cells. Mol. Cancer Ther. 2009, 8. [CrossRef] Willett, C.G.; Boucher, Y.; di Tomaso, E.; Duda, D.G.; Munn, L.L.; Tong, R.T.; Chung, D.C.; Sahani, D.V.; Kalva, S.P.; Kozin, S.V.; et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 2004, 10, 145–147. [PubMed] Dings, R.P.; Vang, K.B.; Castermans, K.; Popescu, F.; Zhang, Y.; Oude Egbrink, M.G.; Mescher, M.F.; Farrar, M.A.; Griffioen, A.W.; Mayo, K.H. Enhancement of T-cell-mediated antitumor response: Angiostatic adjuvant to immunotherapy against cancer. Clin. Cancer Res. 2011, 17, 3134–3145. [PubMed]

Int. J. Mol. Sci. 2017, 18, 2671

29.

30. 31. 32. 33.

34.

35.

36.

37.

38.

39.

40.

41.

42.

9 of 9

Dings, R.P.; Mayo, K.H. A journey in structure-based drug discovery: From designed peptides to protein surface topomimetics as antibiotic and antiangiogenic agents. Acc. Chem. Res. 2007, 40, 1057–1065. [CrossRef] [PubMed] Hudis, C.A. Clinical implications of antiangiogenic therapies. Oncology 2005, 19, 26–31. [PubMed] Bordeaux, J.; Welsh, A.; Agarwal, S.; Killiam, E.; Baquero, M.; Hanna, J.; Anagnostou, V.; Rimm, D. Antibody validation. BioTechniques 2010, 48, 197–209. [CrossRef] [PubMed] Imai, K.; Takaoka, A. Comparing antibody and small-molecule therapies for cancer. Nat. Rev. Cancer 2006, 6, 714–727. [PubMed] Zhang, P.F.; Li, K.S.; Shen, Y.H.; Gao, P.T.; Dong, Z.R.; Cai, J.B.; Zhang, C.; Huang, X.Y.; Tian, M.X.; Hu, Z.Q.; et al. Galectin-1 induces hepatocellular carcinoma emt and sorafenib resistance by activating FAK/PI3K/AKT signaling. Cell Death Dis. 2016, 7, e2201. [CrossRef] [PubMed] Shih, T.-C.; Liu, R.; Fung, G.; Bhardwaj, G.; Ghosh, P.M.; Lam, K.S. A novel galectin-1 inhibitor discovered through one-bead two-compound library potentiates the antitumor effects of paclitaxel in vivo. Mol. Cancer Ther. 2017, 16, 1212–1223. [CrossRef] [PubMed] Martínez-Bosch, N.; Fernández-Barrena, M.G.; Moreno, M.; Ortiz-Zapater, E.; Munné-Collado, J.; Iglesias, M.; André, S.; Gabius, H.-J.; Hwang, R.F.; Poirier, F.; et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and hedgehog signaling activation. Cancer Res. 2014, 74, 3512–3524. [PubMed] Dings, R.P.; Yokoyama, Y.; Ramakrishnan, S.; Griffioen, A.W.; Mayo, K.H. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res. 2003, 63, 382–385. [PubMed] Astorgues-Xerri, L.; De Groot, D.; Serova, M.; Huet, E.; Menashi, S.; Riveiro, M.E.; Cvitkovic, E.; Noel, K.; Raymond, E.; Faivre, S. Targeting galectin-1 with PTX-008 inhibits invasion, tumor growth and metastasis in human carcinoma models. Cancer Res. 2011, 71. [CrossRef] Astorgues-Xerri, L.; Tijeras-Raballand, A.; Riveiro, M.E.; Serova, M.; Martinet, M.; Huet, E.; Menashi, S.; Herait, P.; Cvitkovic, E.; Noel, K.; et al. Antitumor and antiangiogenic effects of OTX-008, a novel calyx[4]arene, are mediated by galectin-1 inhibition in human tumor xenograft models. Cancer Res. 2012, 72. [CrossRef] Dings, R.P.; Levine, J.I.; Brown, S.G.; Astorgues-Xerri, L.; MacDonald, J.R.; Hoye, T.R.; Raymond, E.; Mayo, K.H. Polycationic calixarene PTX013, a potent cytotoxic agent against tumors and drug resistant cancer. Investig. New Drugs 2013, 31, 1142–1150. [CrossRef] [PubMed] Astorgues-Xerri, L.; Riveiro, M.E.; Tijeras-Raballand, A.; Serova, M.; Rabinovich, G.A.; Bieche, I.; Vidaud, M.; de Gramont, A.; Martinet, M.; Cvitkovic, E.; et al. OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis. Eur. J. Cancer 2014, 50, 2463–2477. [PubMed] Pagan, J.; Przybyla, B.; Jamshidi-Parsian, A.; Gupta, K.; Griffin, R.J. Blood outgrowth endothelial cells increase tumor growth rates and modify tumor physiology: Relevance for therapeutic targeting. Cancers 2013, 5, 205–217. [CrossRef] [PubMed] Koonce, N.A.; Levy, J.; Hardee, M.E.; Jamshidi-Parsian, A.; Vang, K.B.; Sharma, S.; Raleigh, J.A.; Dings, R.P.; Griffin, R.J. Targeting artificial tumor stromal targets for molecular imaging of tumor vascular hypoxia. PLoS ONE 2015, 10, e0135607. © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).